Annual report pursuant to Section 13 and 15(d)

General (Details Narrative)

v3.21.1
General (Details Narrative) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Jul. 27, 2020
Apr. 15, 2020
Feb. 27, 2019
Dec. 31, 2018
Accumulated losses $ (47,281) $ (17,508)        
Working capital 5,619          
Shareholders' deficit (11,011) (6,249)       $ (1,216)
Cash and cash equivalents 935 12   $ 1,450    
Recognized revenue 5,207          
Private Placement Transactions [Member]            
Proceeds from issuance of financial instruments 2,617 295        
Convertible Bridge Loans Transactions [Member]            
Proceeds from issuance of financial instruments 4,126 $ 1,374        
Straight loans [Member]            
Proceeds from issuance of financial instruments 1,574          
Credit Line [Member]            
Proceeds from issuance of financial instruments $ 2,368          
Assignment of License Agreement [Member] | Breakthrough Diagnostics, Inc. [Member]            
Ownership percentage     80.01%   19.99%